| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
14,410,000 |
| Market
Cap: |
4.80(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3333 - $0.3333 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ARCA biopharma is a clinical-stage biopharmaceutical company. Co.'s primary product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2 (AB201)) as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro™ (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
183,171 |
| Total Buy Value |
$0 |
$0 |
$0 |
$421,674 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
8 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mott David M |
10% Owner |
– – • |
2018-02-26 |
4 |
S |
$0.50 |
$731,273 |
I/I |
(1,460,209) |
0 |
|
- |
|
| Sakoda Jon |
10% Owner |
– – • |
2018-02-26 |
4 |
S |
$0.50 |
$731,273 |
I/I |
(1,460,209) |
0 |
|
- |
|
| Viswanathan Ravi |
10% Owner |
– – • |
2018-02-26 |
4 |
S |
$0.50 |
$731,273 |
I/I |
(1,460,209) |
0 |
|
- |
|
| Sonsini Peter W. |
10% Owner |
– – • |
2018-02-26 |
4 |
S |
$0.50 |
$731,273 |
I/I |
(1,460,209) |
0 |
|
- |
|
| Baskett Forest |
10% Owner |
– – • |
2018-02-26 |
4 |
S |
$0.50 |
$731,273 |
I/I |
(1,460,209) |
0 |
|
- |
|
| Makower Joshua |
10% Owner |
– – • |
2018-02-26 |
4 |
S |
$0.50 |
$731,273 |
I/I |
(1,460,209) |
0 |
|
- |
|
| Conway Robert |
Chairman of the Board |
– • – |
2017-07-14 |
4 |
B |
$2.49 |
$24,900 |
D/D |
10,000 |
35,000 |
2.39 |
- |
|
| Mitchell Daniel J |
Director |
– • – |
2017-05-02 |
4 |
B |
$2.71 |
$29,810 |
D/D |
11,000 |
11,000 |
2.39 |
- |
|
| Ozeroff Christopher David |
S.V.P., General Counsel |
• – – |
2017-04-04 |
4 |
AS |
$2.41 |
$1,007 |
D/D |
(418) |
17,517 |
|
- |
|
| Bristow Michael R |
Pres. & Chief Executive Offic |
• • – |
2017-04-04 |
4 |
AS |
$2.41 |
$1,735 |
D/D |
(720) |
41,155 |
|
- |
|
| Keuer Thomas A |
Chief Operating Officer |
• – – |
2017-04-04 |
4 |
AS |
$2.41 |
$940 |
D/D |
(390) |
14,045 |
|
- |
|
| Selby Brian L. |
VP, Finance |
• – – |
2017-04-03 |
4 |
AS |
$2.46 |
$2,740 |
D/D |
(1,114) |
1,275 |
|
- |
|
| Conway Robert |
Director |
– • – |
2017-03-24 |
4 |
B |
$2.59 |
$64,750 |
D/D |
25,000 |
25,000 |
2.39 |
- |
|
| Keuer Thomas A |
Chief Operating Officer |
• – – |
2017-02-28 |
4 |
AS |
$2.61 |
$1,214 |
D/D |
(465) |
14,435 |
|
- |
|
| Ozeroff Christopher David |
S.V.P., General Counsel |
• – – |
2017-02-28 |
4 |
AS |
$2.61 |
$1,214 |
D/D |
(465) |
17,935 |
|
- |
|
| Bristow Michael R |
Pres. & Chief Executive Offic |
• • – |
2017-02-28 |
4 |
AS |
$2.61 |
$1,991 |
D/D |
(763) |
41,875 |
|
- |
|
| Selby Brian L. |
VP, Finance |
• – – |
2017-02-27 |
4 |
AS |
$2.56 |
$412 |
D/D |
(161) |
2,389 |
|
- |
|
| Hove Anders D |
Director |
– • – |
2017-02-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,541,331 |
|
- |
|
| Keuer Thomas A |
Chief Operating Officer |
• – – |
2016-10-18 |
4 |
AS |
$2.45 |
$1,184 |
D/D |
(483) |
14,900 |
|
- |
|
| Ozeroff Christopher David |
S.V.P., General Counsel |
• – – |
2016-09-20 |
4 |
AS |
$2.89 |
$3,425 |
D/D |
(1,185) |
18,400 |
|
- |
|
| Bristow Michael R |
Pres. & Chief Executive Offic |
• • – |
2016-09-20 |
4 |
AS |
$2.89 |
$5,699 |
D/D |
(1,972) |
42,638 |
|
- |
|
| Keuer Thomas A |
Chief Operating Officer |
• – – |
2016-09-20 |
4 |
AS |
$2.89 |
$2,063 |
D/D |
(714) |
15,383 |
|
- |
|
| Selby Brian L. |
VP, Finance |
• – – |
2016-09-19 |
4 |
AS |
$2.91 |
$1,385 |
D/D |
(476) |
2,550 |
|
- |
|
| Keuer Thomas A |
Chief Operating Officer |
• – – |
2016-04-05 |
4 |
AS |
$3.52 |
$1,352 |
D/D |
(384) |
16,097 |
|
- |
|
| Bristow Michael R |
See Remarks |
• • – |
2016-04-05 |
4 |
AS |
$3.52 |
$2,548 |
D/D |
(724) |
44,610 |
|
- |
|
115 Records found
|
|
Page 3 of 5 |
|
|
